VistaGen completes enrollment in mid-stage depression med study

Thinly traded nano cap VistaGen Therapeutics (OTC:VTGN +10.4%) is up on below-average volume, a modest 140K shares, on the heels of its announcement that its Phase 2 ELEVATE study evaluating AV-101 for the adjunctive treatment of major depressive disorder is now fully enrolled with 180 participants.

The primary endpoint is the change from baseline to week 2 in the total score of a depression scale called MADRS-10. Topline data should be available by year-end.

https://seekingalpha.com/news/3492272-vistagen-completes-enrollment-mid-stage-avminus-101-study-shares-10-percent